This Stock 1,000% Over: Is There More Upside Ahead?
A stock that has surged 1,000% in a year can still offer opportunity — if you know where to look. This guide breaks d...
Ways To Reduce Subscription Services
Identify and prune unused or duplicative subscriptions with a simple audit. This intro covers tracking, prioritizing, and scaling back renewals.
19,895 articlesRemitly Sells $1.2m Company: What Investors Should Know
When a top Remitly executive sells shares, investors want to know what it means. This guide explains insider sales, h...
Prediction: Spacex Will Greatest IPO Fleece Risk for Retail
SpaceX IPO chatter has investors buzzing and critics worried. This piece breaks down why the hype could outpace reali...
Elon Musk Says ASML Emerges as Europe’s Greatest Company Yet
Elon Musk says ASML has cemented its status as Europe’s top tech company, a claim that reverberates through chip equi...
XMAG vs MAGS: Betting Against or All-In on Magnificent 7
In 2026, XMAG has surged while MAGS has slipped, underscoring a shift from mega-cap AI bets to broad-market exposure....
David Tepper Cuts Microsoft, Ackman Bets Big in AI Push
In Q1 2026, Tepper’s Appaloosa slashed its Microsoft stake by about 82%, while Bill Ackman’s Pershing Square bought r...
It's Going Work: York's 3D Printer Gun Block Law Faces
New York is weighing a first-of-its-kind rule to block gun prints at the printer. The plan, while aiming to curb ghos...
No-Brainer Right Less Than: Best S&P 500 ETF to Buy Now
Looking for a simple, cost-effective way to access the U.S. stock market? This guide breaks down the no-brainer right...
With SpaceX Ready Included: Should You Invest in the VONG ETF?
As SpaceX readiness enters the Russell 1000 framework, investors ask if the Vanguard VONG ETF belongs in a growth por...
The Options Boom Changing What Investors Buy Now in Crypto
Bitcoin and wider crypto markets are eyeing a massive options expiry as traders lean into volatility bets. The option...
Jazz Pharmaceuticals' Lung Cancer Setback: Stock Impact
A late-stage setback for Jazz Pharmaceuticals' lung cancer drug Zepzelca rattled investors, but the larger story may ...
Analyst Just Declared Lilly the Clear Winner at ADA Conference
The ADA conference spotlighted Lilly and Novo Nordisk in the GLP-1 race. This deep dive explains what the claims mean...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status